RATIONALE 301 Study: Tislelizumab Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma
Year: 2019
Type: article
Abstract: Advanced, unresectable hepatocellular carcinoma (HCC) has a poor prognosis with median life expectancy of approximately 1 year. Overexpression of PD-L1 in tumor cells and PD-1 on tumor-infiltrating T cells has been associated with poorer prognosis, more advanced disease and higher recurrence rates in HCC. Monoclonal antibodies against PD-1 have demonstrated antitumor activity in patients with solid tumors, including HCC. Tislelizumab, an investigational, humanized IgG4 monoclonal antibody with high affinity and binding specificity for PD-1, has demonstrated preliminary antitumor activity in HCC. Here we describe a head-to-head Phase III study comparing the efficacy, safety and tolerability of tislelizumab with sorafenib as first-line treatment in unresectable HCC.
Source: Future Oncology
Institutions: 81th Hospital of PLA, Chinese People's Liberation Army, University of California, Los Angeles, Kindai University Hospital, Kindai University, University College London, Medizinische Hochschule Hannover, Institut Gustave Roussy, Fondation Gustave Roussy, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Istituti Ospitalieri di Cremona, BeiGene (China), Harvard University, Massachusetts General Hospital
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W2938499540